Drug Trial Radar · NCT06007690
A Phase 3 Randomized, Masked, Controlled Trial to Evaluate Efficacy and Safety of Belzupacap Sarotalocan (AU-011) Treatment Compared to Sham Control in Subjects With Primary Indeterminate Lesions or Small Choroidal Melanoma
Last checked: Nov 19, 2026Latest source record: Oct 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
108
Actual
Start
Dec 6, 2023
Primary completion
Nov 15, 2027
Study completion Aug 15, 2028
Sponsor
- Lead sponsor
- Aura BiosciencesIndustry
- Sponsor type
- Industry
- First posted
- Aug 23, 2023
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective is to determine the safety and efficacy of belzupacap sarotalocan (bel-sar) compared to sham control in patients with primary indeterminate lesions (IL) or small choroidal melanoma (CM).
Conditions
- Choroidal Melanoma
- Indeterminate Lesions
- Uveal Melanoma
- Ocular Melanoma
Interventions
Bel-sarDrug
Bel-sar via suprachoroidal administration followed by laser application.
Suprachoroidal MicroinjectorDevice
Suprachoroidal injection device
Infrared LaserDevice
Laser application
Sham Infrared LaserDevice
Sham laser application
Sham MicroinjectorDevice
Sham injection device
Primary outcomes
What the sponsor says the trial is designed to measure.
- Time to reach tumor progressionTime frame: 65 weeks
Locations
53 sites in 14 countries. Site status is shown where the registry gives one.
Doris Stein Eye Research Center
Los Angeles, California
Stanford University School of Medicine
Palo Alto, California
Retinal Consultants Medical Group, Inc.
Sacramento, California
Emory Eye Center
Atlanta, Georgia
University of Illinois at Chicago
Chicago, Illinois
Tufts Medical Center New England Eye Center
Boston, Massachusetts
Massachusetts Eye and Ear
Boston, Massachusetts
W.K. Kellogg Eye Center - University of Michigan
Ann Arbor, Michigan
Associated Retinal Consultants (ARC) P.C.
Royal Oak, Michigan
Mayo Clinic
Rochester, Minnesota
Columbia University Irving Medical Center
New York, New York
Cole Eye Institute
Cleveland, Ohio
Dean McGee Eye Institute
Oklahoma City, Oklahoma
Retina Consultants of Oklahoma
Oklahoma City, Oklahoma
Shields & Shields PC-Wills Eye Institute
Philadelphia, Pennsylvania
Retina Consultants of Carolina
Greenville, South Carolina
Tennessee Retina, PC
Nashville, Tennessee
Austin Retina Associates
Austin, Texas
Texas Retina Associates
Dallas, Texas
Eye Cancer Associates of Texas
Houston, Texas
Retina Center of Texas
Southlake, Texas
Retina Associates of Utah
Salt Lake City, Utah
Vitreoretinal Associates of Washington
Bellevue, Washington
University of Washington Medical Center
Seattle, Washington
University of Wisconsin Madison
Madison, Wisconsin
Eye Research Australia
East Melbourne, Victoria, Australia
Medical University Graz
Graz, Austria
Medizinische Universität Wien, Department of Ophthalmology and Optometry
Vienna, Austria
Cliniques universitaires Saint-Luc
Brussels, Belgium
Serac Eye and Skin Care Centre
Calgary, Alberta, Canada
Ustredni vojenska nemocnice Vojenska fakultni nemocnice Praha
Prague, Czechia
Fakultni Thomayerova nemocnice
Prague, Krč, Czechia
Fakultni nemocnice Plzen
Pilsen, Plzenský Kraj, Czechia
Centre Hospitalier Universitaire de Nice
Nice, Cedex 1, France
Hospices Civils de Lyon - Hôpital de La Croix Rousse - Hospital
Lyon, Rhone, France
Charité - Universitätsmedizin Berlin KöR
Berlin, Germany
Universitätsmedizin Essen
Essen, Germany
Uniklinikum Hamburg Eppendorf
Hamburg, Germany
Klinikum der LMU Muenchen
München, Germany
The Chaim Sheba Medical Center
Tel-Hashomer, Central District, Israel
Showing 40 of 53 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.